113 related articles for article (PubMed ID: 15194007)
1. Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP.
Yung HW; Wyttenbach A; Tolkovsky AM
Biochem Pharmacol; 2004 Jul; 68(2):351-60. PubMed ID: 15194007
[TBL] [Abstract][Full Text] [Related]
2. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
3. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MEK/ERK1/2 signalling alters endothelial nitric oxide synthase activity in an agonist-dependent manner.
Cale JM; Bird IM
Biochem J; 2006 Sep; 398(2):279-88. PubMed ID: 16716148
[TBL] [Abstract][Full Text] [Related]
5. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
6. The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer.
Klein PJ; Schmidt CM; Wiesenauer CA; Choi JN; Gage EA; Yip-Schneider MT; Wiebke EA; Wang Y; Omer C; Sebolt-Leopold JS
Neoplasia; 2006 Jan; 8(1):1-8. PubMed ID: 16533420
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA2 phosphorylation and translocation.
Evans JH; Fergus DJ; Leslie CC
BMC Biochem; 2002 Oct; 3():30. PubMed ID: 12370087
[TBL] [Abstract][Full Text] [Related]
8. Glucose dependence of glycogen synthase activity regulation by GSK3 and MEK/ERK inhibitors and angiotensin-(1-7) action on these pathways in cultured human myotubes.
Montori-Grau M; Tarrats N; Osorio-Conles O; Orozco A; Serrano-Marco L; Vázquez-Carrera M; Gómez-Foix AM
Cell Signal; 2013 May; 25(5):1318-27. PubMed ID: 23453973
[TBL] [Abstract][Full Text] [Related]
9. Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.
Miranda MB; McGuire TF; Johnson DE
Leukemia; 2002 Apr; 16(4):683-92. PubMed ID: 11960350
[TBL] [Abstract][Full Text] [Related]
10. Activation of Akt1 by human 5-hydroxytryptamine (serotonin)1B receptors is sensitive to inhibitors of MEK.
Hsu EH; Lochan AC; Cowen DS
J Pharmacol Exp Ther; 2001 Aug; 298(2):825-32. PubMed ID: 11454948
[TBL] [Abstract][Full Text] [Related]
11. CX-659S, a diaminouracil derivative, indirectly inhibits the function of Langerhans cells by blocking the MEK1/2-Erk1/2 pathway in keratinocytes.
Uchi H; Koga T; Urabe K; Moroi Y; Furue M
J Invest Dermatol; 2003 Jun; 120(6):983-9. PubMed ID: 12787125
[TBL] [Abstract][Full Text] [Related]
12. BH(4) (tetrahydrobiopterin)-dependent activation, but not the expression, of inducible NOS (nitric oxide synthase)-2 in proinflammatory cytokine-stimulated, cultured normal human astrocytes is mediated by MEK-ERK kinases.
Chiarini A; Dal Pra I; Gottardo R; Bortolotti F; Whitfield JF; Armato U
J Cell Biochem; 2005 Mar; 94(4):731-43. PubMed ID: 15565652
[TBL] [Abstract][Full Text] [Related]
13. Cerulein-induced acute pancreatitis in the rat is significantly ameliorated by treatment with MEK1/2 inhibitors U0126 and PD98059.
Clemons AP; Holstein DM; Galli A; Saunders C
Pancreas; 2002 Oct; 25(3):251-9. PubMed ID: 12370536
[TBL] [Abstract][Full Text] [Related]
14. PD98059 and U0126 activate AMP-activated protein kinase by increasing the cellular AMP:ATP ratio and not via inhibition of the MAP kinase pathway.
Dokladda K; Green KA; Pan DA; Hardie DG
FEBS Lett; 2005 Jan; 579(1):236-40. PubMed ID: 15620719
[TBL] [Abstract][Full Text] [Related]
15. Aryl hydrocarbon receptor activation and cytochrome P450 1A induction by the mitogen-activated protein kinase inhibitor U0126 in hepatocytes.
Andrieux L; Langouët S; Fautrel A; Ezan F; Krauser JA; Savouret JF; Guengerich FP; Baffet G; Guillouzo A
Mol Pharmacol; 2004 Apr; 65(4):934-43. PubMed ID: 15044623
[TBL] [Abstract][Full Text] [Related]
16. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes.
Liang Q; Wiese RJ; Bueno OF; Dai YS; Markham BE; Molkentin JD
Mol Cell Biol; 2001 Nov; 21(21):7460-9. PubMed ID: 11585926
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of MEK inhibitors on rat neural stem cell differentiation: Repressive roles of MEK2 in neurogenesis and induction of astrocytogenesis by PD98059.
Lee HR; Lee J; Kim HJ
Pharmacol Res; 2019 Nov; 149():104466. PubMed ID: 31562895
[TBL] [Abstract][Full Text] [Related]
18. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
[TBL] [Abstract][Full Text] [Related]
19. The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice.
Brown CN; Atwood DJ; Pokhrel D; Ravichandran K; Holditch SJ; Saxena S; Miyazaki M; Nemenoff R; Weiser-Evans MCM; Ljubanovic DG; Joy MS; Edelstein CL
Cell Signal; 2020 Jul; 71():109605. PubMed ID: 32194168
[TBL] [Abstract][Full Text] [Related]
20. Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells.
Rice PL; Washington M; Schleman S; Beard KS; Driggers LJ; Ahnen DJ
Cancer Res; 2003 Feb; 63(3):616-20. PubMed ID: 12566304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
